Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-13-014390
Filing Date
2013-11-12
Accepted
2013-11-12 07:53:22
Documents
11
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q furx20130930_10q.htm 10-Q 639552
2 EXHIBIT 31.1 ex31-1.htm EX-31 10831
3 EXHIBIT 31.2 ex31-2.htm EX-31 10905
4 EXHIBIT 32.1 ex32-1.htm EX-32 5439
5 EXHIBIT 32.2 ex32-2.htm EX-32 5483
  Complete submission text file 0001437749-13-014390.txt   2459971

Data Files

Seq Description Document Type Size
6 EXHIBIT 101.INS furx-20130930.xml EX-101.INS 161599
7 EXHIBIT 101.SCH furx-20130930.xsd EX-101.SCH 31573
8 EXHIBIT 101.CAL furx-20130930_cal.xml EX-101.CAL 22945
9 EXHIBIT 101.DEF furx-20130930_def.xml EX-101.DEF 127584
10 EXHIBIT 101.LAB furx-20130930_lab.xml EX-101.LAB 231739
11 EXHIBIT 101.PRE furx-20130930_pre.xml EX-101.PRE 128678
Mailing Address 3900 PARAMOUNT PARKWAY SUITE 150 MORRISVILLE NC 27560
Business Address 3900 PARAMOUNT PARKWAY SUITE 150 MORRISVILLE NC 27560 919-456-7800
Furiex Pharmaceuticals, Inc. (Filer) CIK: 0001484478 (see all company filings)

EIN.: 271197863 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34641 | Film No.: 131207000
SIC: 2834 Pharmaceutical Preparations